Omeprazole is a commonly prescribed proton pump inhibitor (PPI) to
reduce acidity. The drug is approved by the regulatory agencies for
the treatment of heartburn and other symptoms associated with
gastroesophageal reflux disease (GERD). Omeprazole is also used to
promote healing of erosive esophagitis (esophageal damage caused by
stomach acid).
Omeprazole is used in combination with antibiotics such as
amoxicillin and clarithromycin for treating ulcers caused by the H.
pylori bacteria.
The
global omeprazole market size was valued at US$ 2,668.4 million in
2017, and is expected to exhibit a CAGR of 5.2% over the forecast
period (2018 – 2026).
Request
PDF Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/2380
Increasing
prevalence of peptic ulcers is expected to propel omeprazole market
growth
Increasing prevalence of duodenal ulcers is expected to propel growth
of the omeprazole market. According to a survey by Virtual Medical
Center, 2016, peptic ulcer is the most common disease occurring in
about 10-15% of the global population at a time. It is common in men
and more common in elderly people. The survey further stated that
duodenal ulcers are four times more common than gastric ulcers.
Also, increasing awareness activities for the treatment of
gastrointestinal disorders by various organizations is a major factor
bolstering market growth. For instance, the International Foundation
for Functional Gastrointestinal Disorders (IFFGD), a nonprofit
education and research organization helps to improve the life of
people affected by chronic digestive conditions. IFFGD enhances
awareness, supports research, for treating gastrointestinal disorders
and educate individuals.
Increasing
prevalence of H.pylori associated infection and favorable pricing
policies to bolster the market growth
North America is expected to hold a dominant position in the global
omeprazole market. This is owing to increasing number of people
affected by H.pylori infection, which in turn is expected to increase
the risk of gastric and duodenal ulcers. According to the National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
Health Information Center, 2014, about 30 to 40 percent of people in
the U.S. suffer from the H. pylori infection, thus increasing the
risk of duodenal and gastric development.
Key
Players
Major players operating in the global omeprazole market include,
Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s
Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc,
Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals
d.d.
Detailed
Segmentation:
Global
Omeprazole Market, By Dosage Form:
-
Capsule
-
Powder
-
Tablet
Global
Omeprazole Market, By Indication:
-
Duodenal Ulcer
-
Gastric Ulcer
-
Gastroesophageal Reflux Disease (GERD)
-
Erosive Esophagitis
-
Others
Get
Full Access of This Business Report:
https://www.coherentmarketinsights.com/market-insight/omeprazole-market-2380
About
Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment